Baird Financial Group
AKBA icon

Baird Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Baird Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,393
Closed -$58.4K – 1791
2025
Q3 		$58.4K Hold
21,393
– – ﹤0.01% 1783
2025
Q2 		$77.9K Hold
21,393
– – ﹤0.01% 1751
2025
Q1 		$41.1K Buy
21,393
+4,000
+23% +$8.16K ﹤0.01% 1740
2024
Q4 		$33K Hold
17,393
– – ﹤0.01% 1741
2024
Q3 		$23K Hold
17,393
– – ﹤0.01% 1741
2024
Q2 		$17.7K Buy
17,393
+1,650
+10% +$2.04K ﹤0.01% 1749
2024
Q1 		$28.8K Buy
15,743
+3,000
+24% +$4.8K ﹤0.01% 1740
2023
Q4 		$15.8K Hold
12,743
– – ﹤0.01% 1700
2023
Q3 		$14.5K Buy
+12,743
New +$16.4K ﹤0.01% 1701
2017
Q4 		– Sell
-10,285
Closed -$202K – 1259
2017
Q3 		$202K Buy
+10,285
New +$158K ﹤0.01% 1179

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baird Financial Group's AKBA Position: Q4 2025 in Review

Baird Financial Group sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 21,393 shares — an estimated $58.4K sold.

Baird Financial Group first reported a position in AKBA in Q3 2017 and held it in 10 quarters. The position peaked at $202K in Q3 2017. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Baird Financial Group reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Baird Financial Group sold 21,393 Akebia Therapeutics shares in Q4 2025, an estimated $58.4K.
  • Baird Financial Group first reported a position in Akebia Therapeutics in Q3 2017 and held it in 10 quarters.
  • Baird Financial Group's Akebia Therapeutics position peaked at $202K in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Baird Financial Group's 13F filing for Q4 2025, filed 13 Feb 2026.